Compare

CTS/$CTS

1D1W1M3M6MYTD1Y5YMAX

About CTS

CTS Corp operates in the electronics industry. The company is a manufacturer of Sensors, Electronic components, and Actuators. It designs, manufactures, and sells a broad line of sensors, electronic components, and actuators mainly to original equipment manufacturers (OEMs) for the aerospace and defense, industrial, information technology, medical, telecommunications, and transportation markets. Geographically, it derives a majority of its revenue from the United States and also has a presence in China, Singapore, the Czech Republic, Taiwan, Denmark, and other countries.
Ticker
$CTS
Sector
Digital Hardware
Primary listing
NYSE
Employees
3,492

CTS Metrics

BasicAdvanced
$1.7B
23.99
$2.54
0.99
$0.16
0.26%

What the Analysts think about CTS

Analyst ratings (Buy, Hold, Sell) for CTS stock.
Analyst projections of the future price of CTS stock.

Bulls say / Bears say

CTS raised its 2026 sales outlook to $580–590 million and adjusted EPS outlook to $2.78–2.88 after another year-on-year increase in quarterly sales and earnings. That signals stronger near-term operating momentum than management had previously expected. (GlobeNewswire)
Industrial sales grew 7% and bookings exceeded shipments, while aerospace and defence bookings were also strong, with a 1.91 book-to-bill ratio. Those order trends could support future growth across markets beyond transport. (Investing.com)
The completed $50 million Millar acquisition adds advanced pressure-sensing technology for medical, life-sciences and industrial uses. It gives CTS another route to broaden its customer base beyond transport. (CTS Corporation)
Management expects global light-vehicle production to be flat to modestly lower, citing tariff, geopolitical and consumer-demand uncertainty. That could constrain CTS’s transport business even as other markets grow. (Investing.com)
The 42.2% adjusted gross margin was a record, and management expects some normalisation from that level. If margins ease, recent profit growth may be harder to sustain. (Investing.com)
Medical bookings lagged shipments, with a book-to-bill ratio of 0.66 as new business wins were affected by order timing. If bookings do not recover, this could weaken near-term revenue visibility in a key growth market. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.

CTS Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

CTS Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.